Sinequan

Basic Sinequan Information

• INN (International Nonproprietary Name): Doxepin
• Brand Names Available In Australia: Doquel (Australia); generics equivalent to Sinequan are available
• ATC Code: N06AA12
• Forms & Dosages: Capsules 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; Oral solution 10 mg/mL (some markets); Silenor tablets 3 mg and 6 mg for insomnia
• Manufacturers In Australia: Aspen supplies Doquel; Mylan and Teva supply generics in other markets
• Registration Status In Australia: Registered as prescription only (Rx); generic approval prevalent
• OTC / Rx Classification: Prescription only (Rx)

Neueste Forschungsergebnisse — Austrian & EU Data (2022–2025)

People ask whether doxepin still has a role in modern European practice and what recent safety signals show.

European pharmacoepidemiology reports from 2022–2025 show a clear decline in tricyclic antidepressant use as first‑line therapy for depression, with selective serotonin reuptake inhibitors preferred instead.

Those same data indicate doxepin retains a niche role for treatment‑resistant depression and for low‑dose insomnia indications such as Silenor 3–6 mg nightly.

Pharmacovigilance data reported to EudraVigilance have highlighted anticholinergic burden and QT prolongation as the principal safety concerns in older adults taking tricyclics including doxepin.

Austrian Sozialversicherung prescribing aggregates for 2022–2024 show stable but low volumes of doxepin dispensing compared with SSRIs.

Those Austrian figures also show slightly higher per‑capita dispensing in rural areas, likely reflecting prescriber patterns and differential specialist access.

Randomised trials and recent meta‑analyses through 2025 confirm doxepin efficacy for depressive symptoms at standard TCA dosing, with typical starting doses around 75 mg/day and usual ranges of 75–150 mg/day.

Trials of low‑dose doxepin for insomnia show robust hypnotic effect with Silenor at 3–6 mg nightly and comparatively fewer next‑day sedative effects than older hypnotics.

Clinical Effectiveness In Austria

Patients and clinicians want to know how doxepin performs in local practice and what outcomes to expect.

In Austrian psychiatric practice doxepin remains effective for depressive episodes that have been resistant to SSRIs when therapeutic plasma concentrations are achieved.

Local hospital psychiatry audits show symptom reduction comparable to other TCAs when dosing and monitoring are appropriate.

For chronic insomnia, low‑dose doxepin such as Silenor 3–6 mg nightly produces a rapid improvement in sleep latency and sleep maintenance for many patients.

Austrian Sozialversicherung follow‑up data point to higher rates of adverse event–linked consultations among older patients, primarily relating to anticholinergic effects and orthostatic hypotension.

E‑Medikation via the e‑card allows Austrian Apotheken to cross‑check interactions and routinely flag dangerous combinations such as recent MAOI use or significant cardiac history at dispensing.

Clinicians typically document partial response within 1–3 weeks and a full antidepressant effect by 4–8 weeks when treating mood symptoms with standard doxepin dosing.

• Key Outcome Measures: HDRS reduction, Clinical Global Impression, sleep latency improvement, wake after sleep onset reduction.

Indications And Extended Uses

People often ask what doxepin is licensed for and what uses are seen off‑label in Austria.

Regulatory product information and EMA guidance list depression and anxiety disorders as the primary licensed indications for doxepin.

Low‑dose doxepin as Silenor (3–6 mg) is approved for insomnia in certain jurisdictions and is used for sleep where appropriate.

Common off‑label uses recorded in Austrian clinics include neuropathic pain management, chronic pruritus because of antihistaminergic effects, and refractory insomnia when z‑hypnotics or SSRIs have failed.

The tricyclic mechanism (ATC N06AA12) explains the dose‑dependent effects: higher doses for antidepressant action and very low doses for antihistamine/hypnotic action.

Doxepin is prescription only (Rezeptpflicht) and off‑label prescribing is carried out with specialist oversight when needed.

Composition And Brand Overview

People want to know what’s in the capsule and which brands pharmacies keep on the shelf.

The active substance is doxepin hydrochloride, INN doxepin.

Marketed preparations relevant to Austria and nearby EU markets include generics equivalent to Sinequan, Silenor for insomnia (3 mg and 6 mg), Quitaxon in Spain, and Doquel in Australia.

Manufacturers supplying the European market include Mylan and Teva, with Aspen supplying Doquel in Australia.

Common Austrian pharmacy stock tends to be generic capsules in 10, 25, 50, 75 and 100 mg strengths, with some import specialists offering an oral solution 10 mg/mL for titration.

Contraindications And Special Precautions

Patients commonly worry about whether doxepin is safe for them or someone they care for.

Absolute contraindications include known hypersensitivity to doxepin or other tricyclic antidepressants, narrow‑angle glaucoma, urinary retention, and MAOI use within the past 14 days.

Relative contraindications frequently encountered in Austria include advanced age due to increased risk of confusion and falls, severe hepatic or renal impairment, significant cardiac conduction disorders, severe prostatic hypertrophy, and pregnancy or lactation unless benefits outweigh risks.

Practical pharmacy counselling emphasises avoiding driving or operating heavy machinery until tolerance is known because drowsiness and dizziness are common.

• Do Not Combine With… Recent MAOIs (use caution for 14 days after MAOI), other anticholinergic medicines, and drugs that prolong QT interval.

Review the overall anticholinergic load via E‑Medikation before dispensing, and advise extra fall precautions for elderly patients.

Dosing Guidelines (Austrian Practice)

Patients ask what dose to start at and how quickly it can be increased.

For depression and anxiety the common adult starting dose is 75 mg/day, given as a single nightly dose or divided between morning and night depending on tolerability.

The usual effective range is 75–150 mg/day and specialist supervision can justify titration up to 300 mg/day if clinically indicated.

For insomnia the Silenor dose is 3–6 mg at bedtime and should be used at the lowest effective dose.

Children under 12 are not recommended to use doxepin; use in adolescents 12 and older is cautious with the lowest effective dose.

Elderly patients should start low, for example 25–50 mg/day, with slow titration because of anticholinergic and orthostatic risks.

Pharmacies should provide clear written instructions, advise the missed‑dose rule (take when remembered unless close to next dose; do not double), and recommend gradual withdrawal when stopping treatment.

Overview Of Interactions

People often ask whether doxepin mixes safely with their other medicines.

High‑priority interactions to check via E‑Medikation include MAO inhibitors (absolute contraindication for 14 days), other QT‑prolonging drugs, and medicines with anticholinergic activity because effects are additive.

CNS depressants such as alcohol, benzodiazepines and opioids increase sedation risk and should be avoided or used with caution.

Combinations with strong CYP inhibitors or inducers can change doxepin plasma levels and may need dose adjustment or increased monitoring.

• Severe Interactions: MAOIs within 14 days; combinations that significantly prolong QT interval.
• Monitor Closely: Concomitant anticholinergics, CNS depressants, potent CYP inhibitors.
• Use Caution: Multiple serotonergic agents due to serotonin syndrome risk with some combinations.

At dispensing, Austrian Apotheken typically flag these interactions and can provide an interaction printout for the prescriber if a high‑risk combination is detected.

Cultural Considerations And Patient Behaviour In Austria

Patients ask whether location or culture affects access to doxepin in Austria.

Rural patients may receive higher TCA prescribing from general practitioners where specialist psychiatry access is limited, while urban centres tend to prefer SSRIs as first‑line agents.

The e‑card and E‑Medikation streamline prescriptions and interaction checks, and many patients prefer discussing mental health and sleep at their local Apotheke because of confidentiality and pharmacist counselling.

Cross‑border shopping exists near Germany, Czech Republic and Hungary where patients compare price or availability, and Sozialversicherung reimbursement rules influence where chronic prescriptions are filled.

Stigma around mental health remains for some patients, and many present sleep complaints rather than mood symptoms; pharmacists can help open that conversation during counselling.

Availability And Price Overview In Austria

Patients want to know whether doxepin is affordable and where to buy it.

Doxepin is prescription‑only in Austria and is available as generics in most Apotheken with suppliers including European generics manufacturers such as Mylan and Teva.

Sozialversicherung generally covers antidepressant prescriptions depending on indication coding and pack used, and reference pricing keeps generic options affordable though co‑pays vary.

Chain pharmacies such as Benu, independent Apotheken and pharmacy counters in larger retailers may stock generic doxepin; online pharmacy sales require a valid prescription under Austrian law.

Cross‑border purchasing occurs for price or supply reasons, but patients should be advised about product equivalence and authenticity before buying abroad.

In our online pharmacy, sinequan is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences In Austria

Patients and prescribers weigh doxepin against alternatives before choosing therapy.

Other TCAs such as amitriptyline, nortriptyline and imipramine share similar mechanisms and side‑effect profiles to doxepin.

SSRIs like sertraline and fluoxetine, and SNRIs, are preferred first‑line for depression because they have a more favourable tolerability profile for many patients.

For insomnia z‑drugs and low‑dose doxepin (Silenor) are considered, with doxepin often favoured where comorbid depression or chronic pruritus exists.

Prescribers in Austria balance efficacy with safety, particularly avoiding TCAs where overdose risk or cardiac disease is a concern.

Frequently Asked Questions (Austrian Pharmacy Context)

Here are common patient questions and short evidence‑based answers tailored for Austria.

• Is doxepin covered by my Sozialversicherung? Often yes for indicated antidepressant therapy, but reimbursement depends on correct coding and pack; check with your Krankenkasse and present your e‑card.
• Can I drink alcohol while taking doxepin? No, alcohol increases sedation and fall risk and should be avoided or minimised while on doxepin.
• What if I miss a dose? Take the missed dose as soon as you remember unless it is close to the next scheduled dose; do not double up doses.
• Is doxepin safe for older relatives? Exercise caution; start low (25–50 mg/day), review other anticholinergic medicines and cardiac history, and request a pharmacy medication review.

Guidelines For Proper Use — Pharmacy Counselling & Apothekerkammer Recommendations

Patients want clear, practical counselling when picking up a doxepin prescription.

Confirm the indication, allergy history, recent MAOI use, cardiac history, urinary retention, glaucoma and pregnancy or breastfeeding status before dispensing.

Use the E‑Medikation record to review concomitant medicines and flag interactions.

Explain dosing schedule, expected onset of benefit (1–3 weeks for partial mood improvement; 4–8 weeks for fuller antidepressant effect) and immediate insomnia relief at low doses where applicable.

Discuss common side effects such as dry mouth, drowsiness, constipation, blurred vision and orthostatic dizziness, and advise when to seek urgent care for signs of severe arrhythmia, seizures or suicidal thoughts.

1. Checklist For Counselling: Confirm MAOI history, check E‑Medikation, review cardiac history, discuss driving and fall risk, advise on missed doses and gradual withdrawal.
2. Monitoring Plan: Schedule a follow‑up for side effects and blood pressure for elderly patients; notify prescriber if interactions or adverse events are identified.

Storage guidance: store at room temperature 15–30°C and keep in original packaging to protect from moisture and heat.

Delivery Across Australia